Literature DB >> 9832145

New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.

D P Hanger1, J C Betts, T L Loviny, W P Blackstock, B H Anderton.   

Abstract

Paired helical filaments (PHFs) are the structural constituents of neurofibrillary tangles in Alzheimer's disease and are composed of hyperphosphorylated forms of the microtubule-associated protein tau (PHF-tau). Pathological hyperphosphorylation of tau is believed to be an important contributor to the destabilisation of microtubules and their subsequent disappearance from tangle-bearing neurons in Alzheimer's disease, making elucidation of the mechanisms that regulate tau phosphorylation an important research goal. Thus, it is essential to identify, preferably by direct sequencing, all of the sites in PHF-tau that are phosphorylated, a task that is incomplete because of the difficulty to date of purifying insoluble PHF-tau to homogeneity and in sufficient quantities for structural analysis. Here we describe the solubilisation of PHF-tau followed by its purification by Mono Q chromatography and reversed-phase HPLC. Phosphopeptides from proteolytically digested PHF-tau were sequenced by nanoelectrospray mass spectrometry. We identified 22 phosphorylation sites in PHF-tau, including five sites not previously identified. The combination of our new data with previous reports shows that PHF-tau can be phosphorylated on at least 25 different sites.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9832145     DOI: 10.1046/j.1471-4159.1998.71062465.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  115 in total

Review 1.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  Tyrosine nitration within the proline-rich region of Tau in Alzheimer's disease.

Authors:  Juan F Reyes; Yifan Fu; Laurel Vana; Nicholas M Kanaan; Lester I Binder
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

3.  FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease.

Authors:  Waltraud Mair; Jan Muntel; Katharina Tepper; Shaojun Tang; Jacek Biernat; William W Seeley; Kenneth S Kosik; Eckhard Mandelkow; Hanno Steen; Judith A Steen
Journal:  Anal Chem       Date:  2016-03-07       Impact factor: 6.986

4.  Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.

Authors:  Ming Jin; Nina Shepardson; Ting Yang; Gang Chen; Dominic Walsh; Dennis J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-18       Impact factor: 11.205

Review 5.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

6.  Pseudophosphorylation of tau protein directly modulates its aggregation kinetics.

Authors:  Edward Chang; Sohee Kim; Kelsey N Schafer; Jeff Kuret
Journal:  Biochim Biophys Acta       Date:  2010-10-23

7.  Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling.

Authors:  Eva Kickstein; Sybille Krauss; Paul Thornhill; Désirée Rutschow; Raphael Zeller; John Sharkey; Ritchie Williamson; Melanie Fuchs; Andrea Köhler; Hartmut Glossmann; Rainer Schneider; Calum Sutherland; Susann Schweiger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

Review 8.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

9.  Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated.

Authors:  Kanae Ando; Mikiko Oka; Yosuke Ohtake; Motoki Hayashishita; Sawako Shimizu; Shin-Ichi Hisanaga; Koichi M Iijima
Journal:  Biochem Biophys Res Commun       Date:  2016-08-09       Impact factor: 3.575

10.  A possible link between astrocyte activation and tau nitration in Alzheimer's disease.

Authors:  Juan F Reyes; Matthew R Reynolds; Peleg M Horowitz; Yifan Fu; Angela L Guillozet-Bongaarts; Robert Berry; Lester I Binder
Journal:  Neurobiol Dis       Date:  2008-05-02       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.